Literature DB >> 23700715

Pathology of renal cell carcinoma: an update.

Antonio Lopez-Beltran1, Liang Cheng, Alfredo Vidal, Marina Scarpelli, Ziya Kirkali, Ana Blanca, Rodolfo Montironi.   

Abstract

The use of classic and newer methodologies, including histopathology, electron microscopy, immunohistochemistry, cytogenetics, and molecular diagnostic techniques, has greatly influenced distinctions between various types of renal carcinoma. The most recent World Health Organization classification of renal neoplasms encompassed nearly 50 distinctive renal neoplasms. These categories have been expanded during recent years, incorporating newer histotypes, thus suggesting that the next revision of this classification will incorporate some of the recently recognized entities. In this review we examine the clinicopathologic and genetic features of renal carcinomas most often seen in clinical practice. Emphasis is placed on defining risk categories by incorporating pathologic predictive paradmeters and tumor histotypes. Since pathology of renal cell cancer is a rapidly evolving field, we also include brief comments on newer tumor variants for which there currently is not enough clinicopathologic information to permit classification as distinctive tumor histotypes.

Entities:  

Mesh:

Year:  2013        PMID: 23700715

Source DB:  PubMed          Journal:  Anal Quant Cytopathol Histpathol        ISSN: 2578-742X


  8 in total

1.  Renal cell carcinoma: the search for a reliable biomarker.

Authors:  Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal:  Transl Cancer Res       Date:  2017-06       Impact factor: 1.241

2.  Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential.

Authors:  Maria Rosaria Raspollini; Francesca Castiglione; Guido Martignoni; Liang Cheng; Rodolfo Montironi; Antonio Lopez-Beltran
Journal:  Virchows Arch       Date:  2015-10-05       Impact factor: 4.064

3.  Decreased SATB2 expression is associated with metastasis and poor prognosis in human clear cell renal cell carcinoma.

Authors:  Changcheng Guo; Dabo Xiong; Xudong Yao; Wenyu Gu; Haimin Zhang; Bin Yang; Bo Peng; Min Liu; Junhua Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 4.  Molecular targets on the horizon for kidney and urothelial cancer.

Authors:  Joaquim Bellmunt; Bin T Teh; Giampaolo Tortora; Jonathan E Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

5.  TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway.

Authors:  Yuan Fang; Wei Bao; Qiu Rao; Xuan Wang; Qiuyuan Xia; Qin Shen; Xiaojun Zhou; Bing Yao
Journal:  Mol Med Rep       Date:  2017-07-05       Impact factor: 2.952

Review 6.  Oncogenic and tumor suppressive roles of special AT-rich sequence-binding protein.

Authors:  Qiao Yi Chen; Max Costa
Journal:  J Carcinog       Date:  2018-04-05

7.  Overexpression of SNHG12 regulates the viability and invasion of renal cell carcinoma cells through modulation of HIF1α.

Authors:  Qiguang Chen; Wei Zhou; Shu-Qi Du; Da-Xin Gong; Jun Li; Jian-Bin Bi; Zhen-Hua Li; Zhe Zhang; Ze-Liang Li; Xian-Kui Liu; Chui-Ze Kong
Journal:  Cancer Cell Int       Date:  2019-05-14       Impact factor: 5.722

8.  Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes.

Authors:  Moonsik Kim; Jin Woo Joo; Seok Joo Lee; Yoon Ah Cho; Cheol Keun Park; Nam Hoon Cho
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.